Most methods for estimation of rates of RNA production are not applicable in human in vivo clinical studies. We describe here an approach for measuring ribosomal RNA turnover in vivo using [6,6-2 H 2 ]-glucose as a precursor for de novo RNA synthesis. Because this method involves neither radioactivity nor toxic metabolites, it is suitable for human studies.
Variations in both the type and amount of RNA in the cell are pivotal for the regulation of intermediary metabolism. Cellular RNA is in a state of rapid turnover, and various RNA species have widely varying life spans. Messenger RNAs (mRNA) 6 have the shortest survival times, with half-lives of minutes to hours (1 ) , and modification of mRNA stability is an important regulatory point for control of protein translation. Transfer RNAs (tRNA) have longer half-lives, measured as hours to days. Ribosomal RNA (rRNA) persists for several days; estimates for rRNA half-life in vitro range from Ͻ3 days (human fibroblasts) (2 ), through 3.8 days (18S rRNA moiety in H1299 cells) (3 ) , to about 7.5 days (cultured rat fibroblasts) (4 ) .
RNA turnover represents the aggregate rate of synthesis and degradation of all RNA species. Changes in mRNA levels are best addressed using molecular approaches or microarrays. Small RNA species such as tRNA may also be quantified using specific probes. Analyzing rRNA kinetics is more difficult, particularly if human in vivo measurements are envisaged. In animal studies U-C 14 -labeled glucose and cytidylic acid have been used to estimate the turnover in rat organs (5 ) and, in vitro, 3 H-uridine may be used (6 ) . Analogous approaches for clinical studies are, however, limited by the toxicity of such radioactive isotopes.
rRNA kinetics is intimately related to cellular metabolism. Changes in RNA content precede changes in protein metabolism in response to cytokine or hormone action or cell division (7 ) , and changes in RNA turnover must de facto precede changes in RNA content. Dysregulation of ribosome biosynthesis is associ-ated with cancer; for example, overexpression of rRNA may lead to malignant transformation (8 ) . In chronic lymphocytic leukemia cells, investigation using methionine-methyl-tritium revealed defective regulation of new ribosome assembly (9 ) . The dynamic nature of rRNA contrasts with genomic DNA, which remains very stable within nondividing cells. The genomic DNA synthesis rate therefore represents a surrogate for proliferation, a property that has been exploited in recently described methods for measuring cell proliferation using stable (nonradioactive) isotope labeling in vivo in humans (10 -14 ) . Applications include the measurement of lymphocyte kinetics in HIV and HTLV-I infection, malignant cell proliferation in leukemia, and vascular smooth muscle in atheroma formation (15) (16) (17) (18) (19) (20) .
In this study, we set out to develop an analogous isotopic approach for measuring rRNA synthesis in vivo in human clinical studies. We hypothesized that rRNA could be labeled in the same way as DNA (11, 12 ) , with deuterium-labeled glucose through the de novo nucleotide synthesis pathway (Fig. 1A) . In the cell, [6,6- 2 H 2 ]-glucose is phosphorylated and converted via the pentose cycle into [5,5- 2 H 2 ]-phosphoribose pyrophosphate; this process results in labeled precursor for ribonucleotide synthesis. To test this hypothesis, we first performed the 4 steps previously described for DNA labeling: label administration, nucleoside extraction, derivatization, and GC-MS analysis (Fig. 1B) (10 -12, 21 ) . We validated or modified each step until optimized for RNA/ribonucleoside analysis using adenosine as a marker of RNA metabolism. We then investigated total RNA production in rapidly proliferating tissue culture cells in vitro, and then determined whether this approach may be applied in vivo in humans to measure rRNA turnover in circulating lymphocytes and tissue samples.
Materials and Methods

METHOD DEVELOPMENT
Isolation of ribonucleosides from RNA. Ribonucleosides were separated from RNA by sequential digestion with nuclease S1 (18 h, 37°C), phosphodiesterase I (2 h, 37°C), and alkaline phosphatase (1 h, 37°C) (enzymes from Sigma), as previously described (22 ) , and analogous to the approach for DNA (10 -12 ) . Efficiency of digestion was confirmed by HPLC against ribonucleoside standards. Adenosine was separated from other ribonucleosides by use of a solid-phase extraction column (LC-18, Supelco), and purity and efficiency were confirmed by HPLC. 
Derivatization of ribonucleosides and GC-MS analysis.
Derivatization conditions required for GC-MS analysis are a compromise between the formation of the derivative and its destruction. For DNA analysis, deoxydenosine may be converted to its aldonitrile triacetate derivative by reaction with hydroxylamine/pyridine (1% wt/vol, 100°C, 45 min) followed by acetic anhydride (room temperature). Adenosine was derivatized with the same reagents but at varying time and temperature combinations, as described below. Analysis of the aldonitrile tetra-acetate (ATA) derivative was performed by GC-MS (HP-225 column; Agilent 6890/ 5973, Agilent Technologies) under positive chemical ionization with methane. Ions were monitored in selected ion-monitoring mode at m/z 256 and 258 for adenosine and 198 and 200 for deoxyadenosine; these represent the M ϩ0 , M ϩ2 mass isotopomers of the dominant ion after ionization.
We also investigated an alternative derivatization approach generating the pentafluoro triacetate (PFTA) derivative of adenosine, modifying the protocol previously described for deoxyadenosine (10 ) . Samples were reacted with aqueous O-(2,3,4,5,6-pentafluorobenzyl)-hydroxyl-amine hydrochloride solution (1 g/L) and glacial acetic acid at various temperature/time combinations. After the mixtures cooled to room temperature, acetic anhydride and N-methylimidazole were added with rapid mixing. The reaction was allowed to proceed for 15-20 min. After cooling, water was added and the derivative extracted from the aqueous phase with dichloromethane. GC-MS analysis was performed as above but in negative chemical ionization mode (NCI).
IN VITRO LABELING OF CELLS IN TISSUE CULTURE
We performed in vitro studies of label incorporation from [6,6-2 H 2 ]-glucose into cellular RNA with PM1 cells (a clone derived from human cutaneous T-cell lymphoma) grown in suspension (RPMI 1640 media, 10% FCS, Gibco BRL). Media were labeled by adding [6,6-2 H 2 ]-glucose (Cambridge Isotope Laboratories) and cells were cultured for varying periods up to 96 h before harvesting. RNA was extracted by guanidine thiocyanate/phenol extraction in a monophase solution (Trizol Sigma). Media enrichments were confirmed by GC-MS of the ATA derivative of glucose.
IN VIVO LABELING OF HUMAN LYMPHOCYTES AND TISSUE
Peripheral blood cells. A patient with chronic lymphocytic leukemia was given 1g/kg 6,6-2 H 2 -glucose (Cambridge Isotope Laboratories) orally for a period of 10 h, as half-hourly aliquots administerd after a priming dose, as previously described (16, 21 ) . The patient was a 59-year-old man with Binet stage A disease, who had a peripheral blood B-cell count of 8.9 ϫ 10 9 cells/L and an unmutated immunoglobulin variable region heavychain phenotype. The study was granted ethics approval by Bordet Hospital in Brussels, Belgium. The patients gave written informed consent, and all procedures were performed in conformity with the Declaration of Helsinki. Blood samples were taken for estimation of deuterium enrichment at 7 time points from 3-30 days after the day of ingestion of labeled glucose. Peripheral blood mononuclear cells (PBMC) were isolated by Ficoll density gradient centrifugation and CD3 -B cells purified by negative selection using CD14/CD56 and CD3-coupled magnetic beads (MACS, Miltenyi Biotec GmbH). After cryopreservation (RNA-later, Ambion), both DNA and total RNA were extracted; mRNA was isolated from total RNA by use of MicroPoly(A) Purist kit (Ambion). Samples were analyzed for deuterium enrichment as described above. Plasma glucose enrichment was measured using the ATA derivative (monitoring ions m/z 328 and 330) as described (12 ) .
Analysis of RNA synthesis in tissue samples. In vivo RNA turnover in lymph nodes was investigated in lymph node excision biopsy samples from 2 patients. Patient A had non-Hodgkin lymphoma (NHL01). Patient B was undergoing investigational procedures for HIVassociated lymphadenopathy; histology showed Kaposi sarcoma. Labeling consisted of a primed 24-h intravenous infusion of 1.3 g/kg [6,6-2 H 2 ]-glucose (Cambridge Isotope Laboratories) initiated 24 h before the time of biopsy (12 ) . Blood samples for measurement of plasma glucose deuterium enrichment were taken during infusion. Tissues samples were homogenized (Polytron) in Trizol reagent (Sigma), and RNA and DNA were isolated. Deoxyadenosine and adenosine were purified and analyzed for deuterium content by GC-MS as described above.
MODELING AND CALCULATION
We analyzed the kinetics of label incorporation and loss in the in vivo studies by using a mathematical model analogous to that previously described for measurement of DNA/cell turnover (23, 24 ) , as shown in Fig. 1 in the Data Supplement that accompanies the online version of this article at http://www.clinchem. org/content/vol55/issue10. Experimental results were expressed as fractional enrichment (F), defined as the proportion of RNA labeled relative to the labeling rate in its precursor, given by: F ϭ E/b, where E is deuterium enrichment in RNA and b is the deuterium enrichment in plasma glucose, corrected as previously described (12 ) . Fractional enrichment/time curves were modeled and solved using nonlinear least squares regression (Sigmaplot v8.02; SPSS) to yield best-fit values for the fractional synthesis rate of RNA (s), and the fractional loss rate of labeled RNA (l*) according to the relationships:
after labeling (2) where t is time from the beginning of labeling and is the duration of labeling. The derivation of these equations is given in online Supplemental Fig. 1 . Doubling times (t 2 ) and half-lives (t 1/2 ), where given, were calculated as ln2/s and ln2/l*, respectively.
Results
RNA DIGESTION TO RIBONUCLEOSIDES AND DERIVATIZATION OF ADENOSINE
HPLC confirmed high retrievals of adenosine, with Ͼ95% purity, from RNA. When optimal conditions for derivatization of adenosine were investigated, we observed, first, that no appreciable derivatization of adenosine (6 mmol/L) occurred at or below 80°C ( Fig.  2A) . However, at the higher temperatures required for production, the ATA derivative was unstable (Fig. 2B ). An optimal compromise between production and destruction was achieved at 110°C for 2 h, conditions adopted in subsequent experiments. When deoxyribonucleosides and ribonucleosides were derivatized together at 110°C, the derivative of deoxyadenosine formed rapidly and then degraded, whereas the derivative of adenosine formed more slowly (Fig. 2C) . Although there was a crossover point (about 75 min), neither substrate yielded more than 50% of maximum yield under such conditions. We therefore concluded that unless cellular material is available in abundance, it is better to separate DNA and RNA first, then derivatize separately under different conditions. Estimates of the deuterium content of standards, containing known amounts of 5,5-D 2 -ribose (Cambridge Isotope Laboratories), based on the parent and M ϩ2 ion abundances (m/z 256, 258; Fig. 2 , D and E) yielded excellent correlation between measured and predicted values (Fig. 2F) ; subsequently standards were run with all samples for calibration.
When the PFTA derivative was analyzed by NCI (Fig. 3A) , it yielded 2 chromatographic peaks (Fig. 3B) corresponding to cis and trans isomers. Analyses performed at varying temperature and time conditions demonstrated progressive formation of the derivative at 100°C or 110°C. At 100°C the derivative was relatively stable, as shown by the ribose derivative, which forms rapidly (Fig. 3C) . Maximal yields were obtained from adenosine at Ն16 h (Fig. 3C) . Analysis of enriched standards demonstrated that either of the dominant ions, m/z 513 and 433, could be used for quantification (Fig. 3D) ; the former corresponds to the parent ion whereas the latter is consistent with loss of [acetate ϩ HF]. ATA and PFTA derivatives both gave excellent results for enrichment analysis (Fig. 2F and 3D) . The PFTA derivative appeared about 2-3 times more sensitive than ATA in terms of abundance vs amount injected (Fig. 3E ) and in terms of the starting number of cells required to obtain abundances from which isotope ratios could be derived, roughly 1 million for PFTA (Fig. 3F ) and 3 million for ATA. The nonlinearity of Fig.  3F compared to Fig. 3E suggests that some stages of sample processing may be saturable at high cell numbers. The PFTA derivative would thus appear preferable, but if NCI analysis is not available, ATA derivatization is an alternative. The in vitro and in vivo experiments described below were all performed using the ATA derivative with positive chemical ionization analysis.
LABELING OF DIVIDING LYMPHOCYTES IN VITRO
When PM1 cells were grown in labeled media, deuterium enrichment increased progressively in both adenosine from RNA and deoxyadenosine from DNA. Initially adenosine enriched more quickly than deoxyadenosine (Fig. 4) ; in a typical experiment, the fractions of new RNA and DNA at 2 h were estimated to be 4.1% and 0.4%, respectively, and at 6 h 10.9% and 4.1%. The excess of RNA synthesis over DNA synthesis at these earlier time points is likely to result from rapid turnover (and thus labeling) of pools of RNA, such as mRNA and tRNA. Beyond about 6 h the enrichment curves for RNA and DNA become parallel (Fig. 4) , suggesting that new RNA and DNA are being synthesized at similar, very rapid rates. The lack of divergence would be consistent with saturation of rapid turnover RNA subspecies. RNA synthesis beyond this point may correlate so closely with new cell synthesis because of the need to generate a new complement of RNA for each new cell, which dominates RNA metabolism in such rapidly dividing cells. After prolonged incubation, deuterium enrichments converged toward a plateau at about 50% of that for the glucose in the media (Fig. 4) , giving an estimate of the level of labeling of intracellular RNA precursors.
IN VIVO LABELING
Turnover of RNA in peripheral blood leukocytes. To investigate in vivo production of RNA, we used an approach that was analogous to that used in vitro, but several major differences should be noted. First, label-ing in vivo was transient rather than continuous, constituting a "pulse-chase" design. Second, measurements were made during unlabeling rather than labeling. Third, whereas most RNA production in very rapidly dividing tissue-culture cells is related to the production of new RNA for new cells, RNA turnover rates in vivo, in which most cells divide far less frequently, are more likely to reflect intracellular turnover of RNA rather than RNA production related to cell division. Fourth, we considered that labeling curves re- flected almost exclusively the dynamics of rRNA because measurements were delayed until Ն3 days postlabeling to allow equilibration between vascular and extravascular lymphoid compartments, a procedure also used for DNA analysis (24 ) . This selectivity was confirmed by models of RNA dynamics (Fig. 5A) , which demonstrated that mRNA and tRNA would be unlikely to contribute to the total labeling curve beyond 3 days postlabeling.
In peripheral blood from 1 patient with chronic lymphocytic leukemia, CD3
-lymphocytes consisting predominantly of B cells showed significant incorporation of deuterium into both RNA and DNA after labeling. Labeling curves for RNA and DNA followed similar patterns (Fig. 5B) ; RNA labeling reached higher initial levels but then fell more rapidly, consistent with faster turnover than DNA, and became undetectable by day 21. Peak RNA labeling was consistent with a proportional synthesis rate (s) of about 7%/day, equivalent to a doubling time (t 2 ) of approximately 10 days (Fig.  5B) . Labeled total RNA was lost at a rate (l*) of about 15%/day, equivalent to a mean half-life (t 1/2 ) of about 5 days. The disparity between rates of synthesis and loss derives from the fact that synthesis relates to the whole RNA pool, whereas loss reflects only labeled RNA, which may be lost at a rate more rapid than average if the RNA pool is heterogeneous. When mRNA was removed from RNA fractions before analysis, similar, albeit slightly decreased, rates were obtained, about 6% and 12% per day for s and l*, respectively (Fig. 5C ). This finding confirmed that mRNA makes only a small contribution to labeling at these time points. The substantial difference between RNA-and DNA-labeling rates (7.0% vs 2.7%/day, respectively; Fig. 5, B and D) , suggests that these cells are metabolically active and that, in contrast with PM1 cells in tissue culture, most RNA production is not directly attributable to cell division.
TURNOVER OF RNA IN LYMPH NODES
In diseased lymph nodes from 2 patients, substantial rates of RNA turnover were measured. In a node infiltrated with lymphoma (patient A), total RNA production rate was estimated to be 9.6%/day, equivalent to a doubling time (t 2 ) of 7 days (Fig. 6A) . In a node affected by HIV-associated Kaposi sarcoma (patient B), higher rates of RNA turnover were estimated; production rate was 36.9%/day (Fig. 6B ), equivalent to a doubling time of about 2 days. In samples from both study patients RNA turnover greatly exceeded DNA turnover (by 4-and 5-fold), estimated cell proliferation rates being 2.4%/day (t 2 29 days) and 7.7%/day (t 2 9 days) respectively.
Discussion
This study demonstrates the proof-of-principle that in vivo production and disappearance rates for RNA may be estimated from rates of incorporation of deuterium from labeled glucose in clinical studies. The use of a stable isotope avoids radiation exposure, in contrast to some previous approaches, and is safe for human studies. In PBMC, a pulse-chase approach with delayed sampling can be used to selectively target ribosomal RNA turnover.
Ribosomal RNA turnover is of interest for several reasons. In lymphocytes, for example, it distinguishes metabolic from proliferative activity; thus terminally differentiated cells, which lack the ability to divide, may appear quiescent on proliferative assays but may have considerable metabolic activity, manifested as accelerated RNA turnover. Tumor cells may have different metabolic activity from nonmalignant cells, and treatment may modify RNA metabolism (8, 9 ) . Applying this approach to leukemic cells, we demonstrate that although such cells are relatively quiescent in proliferative terms, with a lifespan of months (16, 17 ) , they have significant metabolic activity (Fig. 5) . Further interpretation of the RNA turnover rate of such leukemic cells would be enhanced by comparison with other cell types and lymphocytes in other settings.
The approach we describe may also be used in tissue samples to derive production rates for total RNA. In diseased lymph nodes, rates of RNA labeling suggest high metabolic activity. Comparison with DNA labeling suggests that most RNA production is not simply due to the accumulation of newly divided cells. Because the lag between labeling and measurement (Ͻ24 h) was shorter in these experiments than in those with PBMC, the measured results include short-lived RNA species (mRNA, tRNA) as well as rRNA. Interpretation is lim- ited by lack of comparative information from "normal" lymphoid tissues in these investigations and thus they can be considered only pilot studies; such information could be elucidated in further experiments. Despite this limitation, the feasibility of this approach for clinical studies of tissue samples is clearly demonstrated.
The analysis of deuterium-labeled RNA parallels that used for DNA (10 -12 ) , but different derivatization conditions are required, possibly because of greater stability of the pentose ring of adenosine. Analysis of the ATA derivative of adenosine has previously been described by Boros et al., who used [1, [2] [3] [4] [5] [6] [7] [8] [9] [10] [11] [12] [13] C 2 ]-glucose labeling to investigate the intermediary metabolism of RNA in thiamine-responsive megaloblastic anemia (25 ) . This label is not appropriate for turnover measurements because the 1-carbon is lost during nonoxidative pentose production; the preserved 6-position is thus a preferable labeling site. Because RNA labels through the de novo pathway via 5,5-2 H 2 -phosphoribose pyrophosphate, and because this pathway is more active for purines than pyrimidines, selective analysis of purines is advantageous. An allowance for the contribution of nucleoside salvage or other routes by which nonlabeled pentose moieties might enter the precursor pathway is made by correcting the value used for precursor enrichment (12 ) . An estimate of this correction factor may be made by labeling cells to saturation, as in the experiment shown in Fig. 4 . The value obtained in the experiment shown is the same for both RNA and DNA, consistent with shared precursor pathways. The reason why the asymptote does not reach the previously documented value for DNA precursor dilution [0. 6 -0.65 (12 ) ] is unclear, and further experiments to validate this value in both lymphoid and nonlymphoid cells are indicated. Validation in various cell types under differing conditions would enable wider application of this approach; for example, "resting" lymphocytes may make greater use of the salvage pathway than activated cells (26, 27 ) . However, it should be noted that because DNA and RNA data are corrected by the same dilution factor, any error would not affect the comparisons of RNA and DNA turnover rates shown in Figs. 5 and 6. Choice of label is critical. For fast-turnover moieties such as RNA, the precursor must be rapidly incorporated then rapidly disappear. Glucose, with its short in vivo half-life, is an ideal candidate and may be given intravenously or orally (12, 21 ) . A universal issue in labeling studies is recirculation of label, which is likely to be minimal for deuterated glucose because glucose is rapidly metabolized and deuterium is primarily lost into the very large body water pool after oxidation. Although heavy water ( 2 H 2 O) is useful for labeling DNA in slowly dividing cells, in which incorporation of deuterium takes place over weeks (14, 28 ) , 2 H 2 O would not be suited to RNA analysis because of the relatively high rates of RNA turnover; RNA pools would become saturated with label and useful information obscured.
Reducing RNA turnover to a single parameter is, of course, an oversimplification. Each RNA species, having its own rate of synthesis and degradation, will contribute to the overall pool labeling in proportion to its abundance and labeling rate. The measured value is therefore a composite, as illustrated in Fig. 5A . (Such a model of 3 separate homogenous populations is still excessively reductionist because considerable heterogeneity exists within RNA species.) Furthermore, heterogeneity within sampled cell populations must also be considered; for example lymphoid samples may contain nonmalignant lymphoid and myeloid cells, as well as malignant cells, each with their own proliferation/turnover rate and metabolic profile. Nonetheless, when samples are well defined and carefully analyzed, biologically meaningful comparisons should still be possible.
Further method development could focus on dissecting the relative contribution of different RNA species. We separated mRNA from total RNA from chronic lymphocytic leukemia cells for analysis but did not obtain a sufficient signal for reliable quantification of mRNA alone, although we were able to measure the turnover rate of the total RNA fraction remaining after removal of mRNA. With more cells and/or greater analytic sensitivity, together with earlier sampling time points, experiments with other RNA species would be possible. In these studies, we used samples of 10 6 -10 7 cells; the minimum required for reliable analysis will depend on the RNA content of the cell-type of interest but appears to be around 10 6 cells with the protocol above. This sensitivity range would make PBMC subpopulations in individuals with normal peripheral blood lymphocyte counts amenable to analysis.
These studies describe a generic approach that may be tailored toward specific applications. We envisage this approach being used as a research investigative tool in observational and interventional studies of disease mechanisms, rather than as a diagnostic test. Further protocol development would be determined by the RNA species under investigation and the tissue/cell of interest; in this study we have shown how analyzing rRNA turnover in lymphoid tissues can yield novel insights into disease processes such as leukemia and lymphoma. 
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